At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Aug 4, 2026 at 07:30 ET
Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY and above $253.3M consensus, with diluted EPS of $1.28 beating the $1.15 estimate by 11.5%. The company reiterated full-year WAKIX guidance of $1.0B-$1.04B and disclosed encouraging Phase 1 SAD data for orexin-2 agonist BP-205, supporting a best-in-class profile.
- Q2 2026 WAKIX net revenue $261.3M, +30% YoY vs $200.5M in Q2 2025
- Diluted EPS $1.28 vs consensus $1.15, an 11.5% beat
- Estimated average patients grew 450 to 8,950 in Q2
- Reiterated 2026 WAKIX net revenue guidance of $1.0B-$1.04B
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access